Manulife Singapore has announced a partnership with Guardant Health to provide the ShieldTM multi-cancer detection test to its customers, marking a significant step in cancer prevention. This collaboration makes Manulife the first insurer in Singapore to offer this award-winning test, which screens for 10 common cancers with a single blood draw.
The ShieldTM test, which recently won the Oncology Product Innovation of the Year at the Healthcare Asia Medtech Awards, is part of Manulife’s strategy to promote longevity and holistic well-being. Benoit Meslet, President and CEO of Manulife Singapore, emphasised the importance of early health visibility, stating, “Our role is to help customers take charge of their health and finances with confidence.”
Cancer remains the leading cause of death in Singapore, accounting for 26.5% of all deaths in 2024. The introduction of the ShieldTM test aligns with the country’s shift towards preventive and personalised care. Simranjit Singh, CEO of Guardant Health AMEA, highlighted the test’s potential to reduce barriers to cancer screening, saying, “ShieldTM MCD has the potential to address the growing burden of cancer in Singapore.”
The partnership builds on an existing relationship between the two companies, which already offers the Guardant360® Liquid test for advanced solid tumours. This initiative is part of Manulife’s broader commitment to longevity, supported by the Manulife Longevity Institute, which aims to help people live longer, healthier lives.
